Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02345070. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To evaluate, in comparison with placebo, the efficacy of 2 dose levels/regimens of SAR156597 administered subcutaneously during 52 weeks on lung function of participants with Idiopathic Pulmonary Fibrosis (IPF). Secondary Objectives: To evaluate the efficacy of 2 dose levels/regimens of SAR156597 compared to placebo on IPF disease progression. To evaluate the safety of 2 dose levels/regimens of SAR156597 compared to placebo in participants with IPF.
Study identification
- NCT ID
- NCT02345070
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 327 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 1, 2015 (Actual)
- Primary completion
- May 22, 2017 (Actual)
- Completion
- Aug 14, 2017 (Actual)
- Last update posted
- Mar 24, 2022
2015 – 2017
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840003 | Phoenix | Arizona | 85006 | — |
| Investigational Site Number 840020 | Jacksonville | Florida | 32209 | — |
| Investigational Site Number 840022 | Loxahatchee Groves | Florida | 33470 | — |
| Investigational Site Number 840017 | Atlanta | Georgia | 30322 | — |
| Investigational Site Number 840008 | Decatur | Georgia | 30033 | — |
| Investigational Site Number 840010 | Louisville | Kentucky | 40218 | — |
| Investigational Site Number 840009 | Minneapolis | Minnesota | 55455 | — |
| Investigational Site Number 840006 | Rochester | Minnesota | 55905 | — |
| Investigational Site Number 840026 | Chesterfield | Missouri | 63017 | — |
| Investigational Site Number 840001 | Lebanon | New Hampshire | 03756 | — |
| Investigational Site Number 840002 | Summit | New Jersey | 07901 | — |
| Investigational Site Number 840015 | Jamaica | New York | 11435 | — |
| Investigational Site Number 840023 | Mineola | New York | 11501 | — |
| Investigational Site Number 840012 | New York | New York | 10016 | — |
| Investigational Site Number 840013 | Stony Brook | New York | 11794-8121 | — |
| Investigational Site Number 840014 | Philadelphia | Pennsylvania | 19104 | — |
| Investigational Site Number 840011 | Dallas | Texas | 75390 | — |
| Investigational Site Number 840024 | Everett | Washington | 98208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02345070, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 24, 2022 · Synced Nov 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.